Insider Trading History of Fenton Mary Kay

The following table details the insider trading activities (stock purchases, stock sales, and stock option exercises) of Fenton Mary Kay since 2015. This trader's CIK number is 1378589. At the time of last reporting, Fenton Mary Kay was the Chief Financial Officer of Cullinan Therapeutics, Inc.. (stock ticker symbol CGEM). Also see all insider trading activities at Cullinan Therapeutics, Inc..

Note that in the past Fenton Mary Kay also reported insider trading activities as an insider of the following companies:

Yearly summary of insider trading at Cullinan Therapeutics, Inc. (CGEM) by Fenton Mary Kay

Insider Buying Insider Sales Option Exercises
Year Symbol Shares Value Shares Value Shares Value
2026 CGEM 0 $0 4,398 $59,900 0 $0

Yearly summary of insider trading at Achillion Pharmaceuticals Inc (ACHN) by Fenton Mary Kay

Insider Buying Insider Sales Option Exercises
Year Symbol Shares Value Shares Value Shares Value
2015 ACHN 0 $0 56,625 $648,480 56,625 $98,175


Insider trading activities at 2 companies by Fenton Mary Kay:

1. Cullinan Therapeutics, Inc. (CGEM)

2. Achillion Pharmaceuticals Inc (ACHN)

Table 1. Insider trading of Cullinan Therapeutics, Inc. (CGEM) by Fenton Mary Kay

Trade Date Symbol Trade Type Shares Price ($) Value ($)
2026-02-20 CGEM Sale 4,398 13.62 59,900

Table 2. Insider trading of Achillion Pharmaceuticals Inc (ACHN) by Fenton Mary Kay

Trade Date Symbol Trade Type Shares Price ($) Value ($)
2015-12-28 ACHN Sale 43,500 10.08 438,480
2015-12-28 ACHN Option Ex 43,500 1.05 45,675
2015-01-23 ACHN Sale 13,125 16.00 210,000
2015-01-23 ACHN Option Ex 13,125 4.00 52,500

Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Fenton Mary Kay (Chief Financial Officer of Cullinan Therapeutics, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.



©2023, insider-monitor.com. All rights reserved.